NuCana (NCNA) Operating Leases (2018 - 2025)
NuCana (NCNA) reported Operating Leases of $872589.0 for Q4 2025, up 481.07% on a YoY basis from $150169.7 in Q4 2024, and up 481.07% sequentially from $150169.7 in Q4 2024.
NuCana (NCNA) Operating Leases (2018 - 2025) Analysis & Trends
NuCana (NCNA) has 8 years of Operating Leases data on file, last reported at $872589.0 in Q4 2025.
- For the quarter ending Q4 2025, Operating Leases rose 481.07% year-over-year to $872589.0; the trailing twelve-month figure through Dec 2025 stood at $872589.0 (up 481.07% YoY), and the FY2025 full-year result was $864942.8, up 478.33% from the prior year.
- Operating Leases improved to $872589.0 in Q4 2025, from $150169.7 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $872589.0 in Q4 2025 to a low of $150169.7 in Q4 2024.
- A 5-year average of $444633.8 and a median of $464479.6 in 2022 frame the typical range for Operating Leases.
- Across the five-year window, Operating Leases sank 49.23% in 2023 and soared 481.07% in 2025, its largest moves.
- Tracing NCNA's Operating Leases over 5 years: stood at $500111.9 in 2021, then fell by 7.12% to $464479.6 in 2022, then slumped by 49.23% to $235818.9 in 2023, then slumped by 36.32% to $150169.7 in 2024, then soared by 481.07% to $872589.0 in 2025.
- Business Quant data shows NCNA's Operating Leases at $872589.0 in Q4 2025, $150169.7 in Q4 2024, and $235818.9 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 872,589.03 |
| Dec 31, 2024 | 150,169.72 |
| Dec 31, 2023 | 235,818.86 |
| Dec 31, 2022 | 464,479.62 |
| Dec 31, 2021 | 500,111.94 |
| Dec 31, 2020 | 851,690.90 |
| Dec 31, 2019 | 1.04 Mn |
| Sep 30, 2019 | 304,613.63 |
| Jun 30, 2019 | 378,175.91 |
| Mar 31, 2019 | 443,938.75 |
| Dec 31, 2018 | 558,456.98 |